Advertisement

Topics

CTI BioPharma Announces First Patient Enrolled In Phase II Trial Of Pacritinib In Patients With Myelofibrosis Who Have Thrombocytopenia And Who Have Been Previously Treated With Ruxolitinib

20:00 EDT 31 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: CTI BioPharma Announces First Patient Enrolled In Phase II Trial Of Pacritinib In Patients With Myelofibrosis Who Have Thrombocytopenia And Who Have Been Previously Treated With Ruxolitinib

NEXT ARTICLE

More From BioPortfolio on "CTI BioPharma Announces First Patient Enrolled In Phase II Trial Of Pacritinib In Patients With Myelofibrosis Who Have Thrombocytopenia And Who Have Been Previously Treated With Ruxolitinib"

Quick Search
Advertisement